Compare NTAP & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTAP | EW |
|---|---|---|
| Founded | 1992 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.0B | 52.3B |
| IPO Year | 1996 | 1999 |
| Metric | NTAP | EW |
|---|---|---|
| Price | $197.87 | $92.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 30 |
| Target Price | ★ $211.69 | $101.87 |
| AVG Volume (30 Days) | 2.1M | ★ 3.2M |
| Earning Date | 12-01-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | ★ 11.99 | N/A |
| EPS | ★ 1.88 | 1.07 |
| Revenue | ★ $6,237,000,000.00 | $6,067,600,000.00 |
| Revenue This Year | $18.16 | $11.43 |
| Revenue Next Year | $5.97 | $9.91 |
| P/E Ratio | $115.78 | ★ $88.36 |
| Revenue Growth | 5.59 | ★ 11.55 |
| 52 Week Low | $93.69 | $74.66 |
| 52 Week High | $240.87 | $96.29 |
| Indicator | NTAP | EW |
|---|---|---|
| Relative Strength Index (RSI) | 39.96 | 61.35 |
| Support Level | $155.51 | $82.21 |
| Resistance Level | $209.06 | $93.43 |
| Average True Range (ATR) | 8.82 | 2.08 |
| MACD | -2.37 | 0.71 |
| Stochastic Oscillator | 4.50 | 72.26 |
NetApp Inc is storage hardware provider into a software-driven, cloud-centric data infrastructure company. Its flagship ONTAP data management software, together with a comprehensive portfolio of all-flash, hybrid-flash, and cloud-native solutions, forms the backbone of digital transformation for thousands of enterprises world'wide. Its operations are organized into two segments Hybrid Cloud and Public Cloud. It generates majority of revenue from Hybrid Cloud offers a unified data storage portfolio of storage management and infrastructure solutions that helps customers modernize their data centers. Hybrid Cloud includes software, hardware, and related support, along with professional and other services. It generates majority of revenue from United States followed by International market.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.